Managers / Q1 2026
GSK plc
CIK 0001131399 · 79 NEW OXFORD STREET, LONDON, WC1A 1DG · 44 20 8047 5000
Reported Value
$599M
Q1 2026
Positions
13
Filings on Record
2
2019–present window
Filed
May 14, 2026
original filing
Summary
Gsk Plc reported $599M in U.S.-listed holdings across 13 positions for Q1 2026.
The portfolio is heavily concentrated: Crispr Therapeutics alone accounts for 25.6% of reported value.
Compared with Q4 2025, the fund opened 0 new positions and exited 2.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
Holdings — Q1 2026
Filing History
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.